68856-96-2

Basic information

• Product Name: BOC-D-TYR(ME)-OH
• Synonyms: (2R)-3-(4-methoxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid;Boc-O-methyl-D-tyrosine≥ 98% (HPLC);Boc-π-methoxy-D-Phe-OH;(R)-2-TERT-BUTOXYCARBONYLAMINO-3-(4-METHOXY-PHENYL)-PROPIONIC ACID;N-ALPHA-T-BUTOXYCARBONYL-4-METHOXY-D-PHENYLALANINE;N-ALPHA-T-BOC-O-METHYL-D-TYROSINE;N-ALPHA-T-BOC-P-METHOXY-D-PHENYLALANINE;N-ALPHA-T-BUTOXYCARBONYL-O-METHYL-D-TYROSINE
• CAS NO: 68856-96-2
• Molecular Formula: C₁₅H₂₁NO₅
• Molecular Weight: 295.33
• Product Categories: Unusual Amino Acids;Boc-Amino Acids and Derivative
• Mol File: 68856-96-2.mol

Chemical Properties

• Melting Point: 93.0 to 97.0 °C
• Boiling Point: 462.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.168±0.06 g/cm3(Predicted)
• Storage Temp.: Store at 0-5°C
• PKA: 3.00±0.10(Predicted)
• CAS DataBase Reference: BOC-D-TYR(ME)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-D-TYR(ME)-OH(68856-96-2)
• EPA Substance Registry System: BOC-D-TYR(ME)-OH(68856-96-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 68856-96-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-D-TYR(ME)-OH is used as a building block for the synthesis of cyclic peptides with potential therapeutic applications. Its ability to form β-sheet structures enables the development of peptides with enhanced stability and bioactivity, which can be utilized in the treatment of various diseases and conditions.
Used in Drug Design and Synthesis:
BOC-D-TYR(ME)-OH is used as a key component in the design and synthesis of self-assembling cyclic peptides with tunable cavities. These peptides can be engineered to possess specific functions, such as binding to target molecules or exhibiting enzymatic activity, making them valuable tools in drug discovery and development.
Used in Peptide Chemistry Research:
BOC-D-TYR(ME)-OH is used as a research tool in the field of peptide chemistry, where it can be employed to study the properties and behavior of β-sheet-based cyclic peptides. This knowledge can contribute to the advancement of peptide-based therapeutics and the understanding of their mechanisms of action.

Upstream product

• 122517-80-0 (2S,3R)-(-)-methyl 2,3-dihydroxy-3-(p-methoxyphenyl)propionate 
• 1415012-34-8 methyl 2-azido-3-(4-methoxyphenyl)propanoate 
• 1415012-33-7 methyl 2-bromo-3-(4-methoxyphenyl)propanoate 
• 58236-76-3 3-chloro-4-methoxy cinnamic acid 
• 122517-81-1 (2R,3S)-methyl 2,3-dihydroxy-3-(4-methoxyphenyl)propanoate 
• 832-01-9 methyl p-methoxycinnamate 
• 830-09-1 3-(4'-methoxyphenyl)propenoic acid 
• 241153-85-5 methyl 3-(3-chloro-4-methoxyphenyl)acrylate 
• 3728-20-9 D-tyrosine methylester hydrochloride 
• 76757-90-9 N-(tert-butoxycarbonyl)-D-tyrosine methyl ester 
• 556-02-5 tyrosine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 94790-24-6 (2R)-tert-butoxycarbonylamino-3-(4-methoxyphenyl)propionic acid methyl ester 
• 215454-88-9 N-tert.-butoxycarbonyl-2-(R)-amino-3-(4-methoxyphenyl)-propionic acid benzyl ester 

Downstream Products

• 178977-38-3 3-[(2R)-(tert-butoxycarbonylamino)-3-(4-methoxyphenyl)propanoylamino]propanoic acid 
• 70601-64-8 (R)-4-methoxyphenylalanine methyl ester hydrochloride 
• 644989-76-4 [2-(3,3-dimethyl-2-oxo-azetidin-1-yl)-1-(4-methoxy-benzyl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 728032-80-2 benzyl (2R)-2-[3-[(2R)-2-tert-butoxycarbonylamino-3-(4-methoxyphenyl)propionylamino]propionyloxy]-4-methylpentanoate 
• 221187-06-0 Boc-D-Tyr(Me)-L-Ile-D-Pro-OBzl 
• 591772-23-5 Boc-D-Tyr(Me)-L-Ile-L-Pro-OBzl 
• 591772-34-8 Boc-D-Tyr(Me)-L-Ile-DL-Pip-OBzl 
• 155645-51-5 Cryptophycin 4 
• 124689-64-1 cryptophycin C 
• 182486-25-5 tert-butyl (5S,6R)-5-[(2S)-2-[(2R)-3-[(2R)-2-tert-butoxycarbonylamino-3-(3-chloro-4-methoxyphenyl)propionylamino]-2-methylpropionyloxy]-4-methylpentanoyloxy]-6-methyl-8-phenylocta-2(E),7(E)-dienoate 
• 245125-92-2 tert-butyl (5S,6R)-5-[(2S)-2-[(2R)-3-[(2R)-2-tert-butoxycarbonylamino-3-(4-methoxyphenyl)-propionylamino]-2-methylpropionyloxy]-4-methylpentanoyloxy]-6-methyl-8-phenylocta-2(E),7(E)-dienoate 
• 181656-40-6 (2E,7E)-(S)-5-((S)-2-{(R)-3-[(R)-2-tert-Butoxycarbonylamino-3-(4-methoxy-phenyl)-propionylamino]-2-methyl-propionyloxy}-4-methyl-pentanoyloxy)-6-oxo-8-phenyl-octa-2,7-dienoic acid tert-butyl ester 
• 1027159-63-2 (2E,7E)-(S)-5-((S)-2-{(R)-3-[(R)-2-tert-Butoxycarbonylamino-3-(3-chloro-4-methoxy-phenyl)-propionylamino]-2-methyl-propionyloxy}-4-methyl-pentanoyloxy)-6-oxo-8-phenyl-octa-2,7-dienoic acid tert-butyl ester 
• 1225439-76-8 tert-butyl [(R)-2-(3-but-2-ynyloxy-3-o-tolyl-azetidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]carbamate 

Relevant articles and documents

Synthesis of unit-B of cryptophycin-24 via Sharpless asymmetric dihydroxylation

A synthetic pathway for the synthesis of unit-B of cryptophycin-24 has been developed using Sharpless asymmetric dihydroxylation as the key step. This study shows that direct azidation of α-hydroxy acid ester using diphenylphosphoryl azide is beneficial to asymmetric synthesis of α-amino acid without the loss of chirality during the transformation.

Discovery of pyrrolopyrimidine inhibitors of Akt

The discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts.

Heterocyclic derivatives and their use as antithrombotic agents

The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X′ being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.